Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating reaffirmed by stock analysts at Liberum Capital in a research note issued to investors on Thursday. They currently have a GBX 245 ($3.16) price objective on the stock. Liberum Capital’s price target points to a potential upside of 55.56% from the company’s previous close.

STX has been the subject of several other reports. Peel Hunt reissued a “buy” rating and set a GBX 220 ($2.84) price objective on shares of Shield Therapeutics PLC in a research note on Thursday, July 6th. FinnCap started coverage on shares of Shield Therapeutics PLC in a research note on Thursday, September 7th. They set a “buy” rating and a GBX 270 ($3.49) price objective for the company.

Shares of Shield Therapeutics PLC (LON STX) opened at 157.50 on Thursday. The stock has a 50 day moving average price of GBX 157.50 and a 200 day moving average price of GBX 163.10. The firm’s market capitalization is GBX 170.10 million. Shield Therapeutics PLC has a 52 week low of GBX 152.25 and a 52 week high of GBX 177.00.

TRADEMARK VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at

About Shield Therapeutics PLC

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Receive News & Stock Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related stocks with our FREE daily email newsletter.